These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 9990469

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R, Malik A, Singhal S.
    Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.
    Ozkutuk A, Ergon C, Metin DY, Yucesoy M, Polat SH.
    J Chemother; 2008 Feb; 20(1):87-92. PubMed ID: 18343749
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
    Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK.
    Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM, Szekely A, Warnock DW.
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [Abstract] [Full Text] [Related]

  • 53. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp.
    Maesaki S, Iwakawa J, Higashiyama Y, Miyazaki Y, Yanagihara K, Tomono K, Tashiro T, Kohno S.
    J Infect Chemother; 2000 Jun; 6(2):101-3. PubMed ID: 11810544
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [Abstract] [Full Text] [Related]

  • 57. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C.
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.
    Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA.
    J Clin Microbiol; 2003 Mar; 41(3):1126-9. PubMed ID: 12624040
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.